In any game of chess, the initial set of moves (termed the chess openings) play a critical role in determining the course and eventually the outcome of the game. In contrast, during the "end game", the strategic options may be limited and eventual outcome strongly biased already towards one side or another. To date, cancer immunologists have focused mostly on the end game, patients with advanced cancer.
While recent successes in the clinic (such as with T cell checkpoint blockade) (1-3) offer optimism even in this setting, we suggest that the field of immuno-oncology would be well served in moving at least part of its attention from the end game to the openings.
Active interventions in this setting might have a greater and longer lasting impact than application of similar strategies to target advanced cancers. In 2011, Nobel Laureate Elizabeth Blackburn proposed a term cancer interception to describe active intervention to halt the progression of cancers in precursor states (4) . Here we modify the term as immune-interception, to specifically discuss immune based approaches with this objective (5).
Cancer as a battle of two adaptive systems
The importance of the cross-talk between tumor cells and the microenvironment is now well appreciated (6) . However, the analogy to the chess match, as noted above, is particularly suited for the interactions of tumors with the immune system, as both of these are highly adaptive systems. The immune system has evolved over a much longer time, and it could be argued, therefore, that a young immune system should have greater adaptive fitness than the nascent or young tumors. With age, however, the available repertoire of T cell receptors diminishes over time, which might contribute to lower adaptive fitness of the aging immune system (7) . Tumors may also differ in their genetic complexity and adaptive potential. For example, many of the pediatric tumors appear to be genetically less complex with fewer mutations per cancer cell (8) . In contrast, several tumors in adults are often genetically more complex and carry extensive sub-clonal evolution (9) . This may in turn facilitate greater capacity for adaptive fitness and eventual immune escape. In addition, over time, growing tumors engage several strategies that may help facilitate escape from active pressure of 
Immune recognition of early tumors
The consequences of early immune recognition have been extensively studied in murine models (12) . These studies have indicated a role for both innate and adaptive immunity in mediating immune surveillance in both spontaneous and carcinogeninduced models. Further, tumors that are not rejected by the immune system can stay in an equilibrium with the immune system and undergo immune selection or editing, eventually contributing to escape of tumors from the immune pressure (13) . Recent studies have also demonstrated the capacity of the immune system to delay the development of autochthonous tumors in mouse models (14) . 
The case for personalized interception
Recent advances in cancer genetics and next generation sequencing are providing unprecedented opportunities for the development and testing of targeted therapeutics in cancer. We suggest that sequencing the genomes of precursor states will yield an equally rich database of genomic alterations and mutations. While the traditional approach in cancer prevention tries to find pathways that could be targeted by drugs, it is possible that such therapies would carry the risk of toxicities due to effects on normal tissues and may require longterm administration. For example, inhibitors of hedgehog signaling were effective in patients with basal cell nevus syndrome, but most lesions recurred after stopping therapy (27) . While the plethora of genetic somatic mutations can be a challenge for pharmacologic approaches for prevention, it is equally a boon for immunologic approaches, as they allow the immune system to specifically target the tumor while sparing normal tissues (28) . potential immune epitopes generated, which in turn could help develop personalized vaccines (29) . It is also useful to remember that even at this "early stage," there is already a naturally occurring host response against these lesions. In this setting, control mechanisms that limit such immune responses may also be operative. Therefore, the optimal strategy for several patients may not be simply to vaccinate in order to elicit or boost immunity against tumors but also to address the mechanisms that may limit the immunogenicity of the vaccines or naturally occurring immunity. Here again, understanding the properties of the host response in the specific patient may allow the correct choice of the combination approach. Alternatively, deeper understanding of the kind of immune suppressive mechanisms operative early on in an individual patient may also aid in patient selection and in limiting patients for vaccine studies to those that lack such responses. It is equally important to note that not all premalignant lesions may be equally likely to transform to clinical malignancy. Therefore, understanding the risk of transformation in a specific premalignant lesion may be essential for balancing the potential risks and benefits of a preventive intervention. Timing is a key element for a successful attack in a chess game: too early and your preparations are incomplete; too late and your opponent has rallied his defenses and even launched a counterattack.
Perhaps the same lessons will apply to harnessing the immune system to prevent 
